Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Clinical Trials
April 2007

Comparison of the Modified Early Treatment Diabetic Retinopathy Study and Mild Macular Grid Laser Photocoagulation Strategies for Diabetic Macular Edema

Writing Committee for the Diabetic Retinopathy Clinical Research Network
Author Affiliations

HYMANLESLIEPhDWriting Committee: The lead authors are Donald S. Fong, MD, (lead author) and Samara F. Strauber, MS. Additional writing committee members are Lloyd Paul Aiello, MD, PhDl; Roy W. Beck, MD, PhD; David G. Callanan, MD; Ronald P. Danis, MD; Matthew D. Davis, MD; Stephen S. Feman, MD; Frederick Ferris, MD; Scott M. Friedman, MD; Charles A. Garcia, MD; Adam R. Glassman, MS; Dennis P. Han, MD; Darma le, MD; Craig Kollman, PhD; Andreas K. Lauer, MD; Franco M. Recchia, MD; and Sharon D. Solomon, MD.


Copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2007

Arch Ophthalmol. 2007;125(4):469-480. doi:10.1001/archopht.125.4.469

Objective  To compare 2 laser photocoagulation techniques for treatment of diabetic macular edema: the modified Early Treatment Diabetic Retinopathy Study (ETDRS) direct/grid photocoagulation technique and a potentially milder (but potentially more extensive) mild macular grid (MMG) laser technique in which microaneurysms are not treated directly and small mild burns are placed throughout the macula, whether or not edema is present.

Methods  Two hundred sixty-three subjects (mean age, 59 years) with previously untreated diabetic macular edema were randomly assigned to receive laser photocoagulation by either the modified ETDRS (162 eyes) or MMG (161 eyes) technique. Visual acuity, fundus photographs, and optical coherence tomography measurements were obtained at baseline and at 3.5, 8, and 12 months. Treatment was repeated if diabetic macular edema persisted.

Main Outcome Measure  Change in optical coherence tomography measurements at 12-month follow-up.

Results  Among eyes with a baseline central subfield thickness of 250 μm or greater, central subfield thickening decreased by an average of 88 μm in the modified ETDRS group and by 49 μm in the MMG group at 12-month follow-up (adjusted mean difference, 33 μm; 95% confidence interval, 5-61 μm; P = .02). Weighted inner zone thickening by optical coherence tomography decreased by 42 μm in the modified ETDRS group and by 28 μm in the MMG group (adjusted mean difference, 14 μm; 95% confidence interval, 1-27 μm; P = .04); maximum retinal thickening (maximum thickening of the central and 4 inner subfields) decreased by 66 and 39 μm, respectively (adjusted mean difference, 27 μm; 95% confidence interval, 6-47 μm; P = .01), and retinal volume decreased by 0.8 and 0.4 mm3, respectively (adjusted mean difference, 0.3 mm3; 95% confidence interval, 0.02-0.53 mm3; P = .03). At 12 months, the mean change in visual acuity was 0 letters in the modified ETDRS group and 2 letters worse in the MMG group (adjusted mean difference, 2 letters; 95% confidence interval, −0.5 to 5 letters; P = .10).

Conclusions  At 12 months after treatment, the MMG technique was less effective at reducing optical coherence tomography–measured retinal thickening than the more extensively evaluated current modified ETDRS laser photocoagulation approach. However, the visual acuity outcome with both approaches is not substantially different. Given these findings, a larger long-term trial of the MMG technique is not justified.

Application to Clinical Practice  Modified ETDRS focal photocoagulation should continue to be a standard approach for treating diabetic macular edema.

Trial Registration Identifier: NCT00071773.